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Abstract
A preformulation study of an oral lyophilisate with cetirizine dihydrochloride (CTZ) as active
ingredient, mannitol and PVP K30 as bulking agents is presented. CTZ shown a humidity
content of 0.150% and a spontaneous hygroscopicity of 0.200% (both determined by
SeDeM diagram), demonstrating an adequate stability behavior in solid form. A design of
experiments (DoE) performed with both mannitol and PVP K30, followed by a simple facto-
rial design (32) has determined the optimum combination of excipients and CTZ, and
showed that a higher proportion of PVP K30 was able to prevent metastable forms gener-
ated by mannitol.
Introduction
Oral lyophilizates (OL) are solid pharmaceutical forms, presenting the advantages of solid and
liquid forms at the same time, such as precise and unique dose, good stability, reduced package
size, easy to swallow (oral route), do not present any gastrointestinal obstruction risk (there-
fore easy to be administered in elderly and children patients) [1]; [2]; [3]; [4]; [5]. A solution,
suspension or emulsion is prepared (containing the active substance), followed by a freeze-
drying process, resulting in a porous solid form that dissolves instantly when in contact with
saliva or water [6]. There are several active ingredients that can be found as OL (antihistamines
such as ebastine and desloratadine, antidiarrheal as loperamide and serotonin 5-HT receptor
antagonist such as ondansetron) [7]. The objective of this study was to develop an OL formula
of a second-generation antihistamine, cetirizine dihydrochloride (CTZ), which can be found
in tablets, chewable gums, extended release tablets, capsules and syrup (liquid)[7]; [8]; [9];
[10]; [11]; [12], being candidate for an OL formulation. Therefore, a preformulation study of
CTZ was performed using powder x-ray diffraction method (PXRD) to determine the rate of
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crystallization and differentiation of polymorphs of CTZ, followed by Nuclear Magnetic Reso-
nance, UV-Vis spectrophotometry (UV-Vis) and Infrared spectrophotometry (IR) to identify
CTZ. In addition, a SeDeM diagram was performed for the acknowledge of the rheology of
CTZ [13]; [14]; [15]; [16]; [17]; [18]. A previous stability-indicating study of HPLC for the
same active substance was already published [19].
Excipients are the main components of a freeze-dried product in general, by giving solid
content, apparent density, resistance against mechanical damage, aesthetic claim (robust
freeze-dried plug aspect). Considering freeze-dried formulas (in general), excipients can bal-
ance pH, if necessary, as buffers; guarantee isotonicity for the reconstituted solution, protect a
bioactive component during the freeze-drying process, confer long term stability to the dry
product. As bulking agents, excipients can generate enhance mechanical resistance by aug-
menting the solid content of the plug, avoiding pulverization of the plug. Bulking agents such
as aspartame, gelatin and mannitol increase the total solid content, creating a firm matrix
(plug) structure. For example, aspartame can be used as sweetener and bulking agent, gelatin
as binder and bulking agent as well. Amongst excipients, there are those with crioprotective
features (such as polyvinylpyrrolidone), which are characterized by protecting components
that may be damaged by the freezing process. Excipients with a high Tg’ (glass transition tem-
perature) allow the execution of shorter freeze-drying cycles, as they rise the maximum tem-
perature for the ice sublimation and therefore, reducing manufacturing costs. When
formulating for a OL, it must be taken into account the physicochemical characteristics of the
active ingredient. For instance, those that are soluble in water (which is the case of CTZ) can
produce euthectic mixtures with very low Tg’, with the formation of vitreous solids which may
suffer collapse (loss of structure) during the sublimation phase of the freeze-drying cycle. One
way to avoid collapse is to use mannitol as bulking agent [7].
The excipients mannitol and polyvinylpyrrolidone K30 (PVP K30) [20] were proposed as
bulking agents for the development of the OL matrix. Mannitol is a polyol used as non-cario-
genic sweetener and a non-hygroscopic excipient which presents a cooling effect due to its
negative heat of solution providing pleasant mouthfeel and sweet taste [21]. Mannitol also
helps avoiding collapse during sublimation [22]. Used as diluent for oral formulations (10–
90% w/w), and as bulking agent for freeze-dried formulas (20–90% w/w), it forms rigid and
elegant cake, with good dispersibility properties [23]. It can present three polymorphic states
when crystalized (α, β and δ) as well as a hydrate. As a hydrate, the bound water can be released
during storage, compromising the stability of the drug [23]; [24].
PVP K30 is an excipient used as binder in tablets formulas and as a solubilizer in oral and
parenteral liquids, and chewable tablets and freeze-dried parenteral formulas [20]; [25]. It pres-
ents a crioprotective feature providing protection for the freeze-dried formula during freezing
[26]. Increases solubility of poorly soluble drugs [27]; [28]; [29]; [30]; [31]; [32]; [33]. It was
also considered as bulking agent candidate for the reason that when combined with mannitol
increases the fracturability of the freeze-dried cake [34]. It may increase or decrease the glass
transition temperature (Tg’), which depends on the relation between PVP, Tg’ and relative
humidity [35]. However, it is not commonly used in OL formulas, which makes it interesting
to acknowledge whether it can be used as bulking agent. A design of experiments (DoE) and a
factorial design 32 among CTZ and the excipients chosen [36] was carried out [37]. Freeze-dry-
ing viability studies (FDVT) within a simple freeze-dried cycle (-40 to 40˚C) were key to
acknowledge with the studied concentrations of excipients, the progressive consistency of the
cake (matrix). Differential Scanning Calorimetry (DSC) was the method used for detecting
metastable forms and determining Tg’. Freeze-drying microscopy (FDM) was used to deter-
mine the collapse temperature (TCO) of all combinations of the 3
2 factorial design.
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The active substance used was cetirizine dihydrochloride (Jubilant Lifesciences Ltd, India;
CTZ). The excipients used for the study SeDeM were talc (Fagron, Spain), magnesium stearate
(Fagron, Spain), and colloidal silicon dioxide (Aerosil1, Fagron, Spain). The excipients used
in the factorial design were mannitol (Fagron, Spain) and polyvinylpyrrolidone Ph. Eur
(Fagron, Spain). The reagents used for the preparation of phosphate buffers solutions (solubil-
ity studies) were: 37% HCl (Panreac, Barcelona), NaCl (Panreac, Barcelona), NaOH (Panreac,
Barcelona) and KH2PO4 (Panreac, BCN).
Methods
SeDeM. Although the main objective of the study is the development of an OL, a SeDeM
diagram (for direct compression purposes) was performed for CTZ to acknowledge its rheo-
logical characteristics. The SeDeMmethodology [13]; [14], is a development method for appli-
cation in tablet-formulation and formulation studies. It is based in the concept of quality by
design (QbD) described in ICH Q8 [36] since it evaluates critical quality attributes (CQA) that
have an impact on the quality of the final product. It provides information about the suitability
of active ingredients and excipients in powder for direct compression. This information indi-
cates the degree to which the substances can be successfully compressed by means of direct
compression technology. The parameters considered are the following: Bulk density (Da),
Tapped density (Dc), Inter-particle porosity (Ie), Carr index (IC), Cohesion index (Icd), Haus-
ner ratio (IH), Angle of repose (α), Powder flow (t´´), Loss on drying (%HR), Hygroscopicity
(%H), Particle size (%Pf) and Homogeneity index (Iϴ). These parameters are determined by
means of the new SeDeM diagram method, based on known equations [13]; [14]; [17]; [18],
and duly validated and reproducible experimental tests, as shown in Table 1.
Once the values have been obtained following the specific methods, the next step is to con-
vert the numeric limits for each SeDeM Diagram parameter to radius values r, in accordance
with Table 2 [13]; [14]; [15]; [16]; [17]; [18]; [38].
When all radius values are 10, the SeDeM Diagram takes the form of a regular polygon,
drawn by connecting the radius values with linear segments. The results obtained from earlier
parameter calculations and conversions are represented by the radius. The figure formed indi-
cates the characteristics of the product (in this case, CTZ) and each of the parameters that
determine whether the product is suitable for direct compression. In this case, the SeDeM Dia-
gram is made of 12 parameters, which would form and irregular 12-sided polygon. To deter-
mine whether the active substance is acceptable for direct compression in numerical form, the
following indexes are calculated based on the SeDeM Diagram as:
Parameter index (IP)
IP = No.p5/No.Pt
No.p5: Indicates the number of parameters whose value is equal to or higher than 5.
No.Pt: Indicates the total number of parameters studied.
The acceptability limit would correspond to: IP5
Parameter profile index (IPP)
IPP = mean r 5 of all parameters
Mean r = mean value of the parameters calculated.
The acceptability limit would correspond to IPP = mean r 5
Good compression index (IGC)
(IGC) = IPP x f
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Where f is the reliability factor and is calculated as follows:
f = Polygon area/circle area
The acceptability limit will be calculated by:
IGC = IPP x f> 5.
Table 2. Parameters and equations used in SeDeMmethodology.
Incidence Parameter Limit value Radius (r) Factor applied to v
Dimension Bulk density 0–1 g/ml 0–10 10 v
Tapped density 0–1 g/ml 0–10 10 v
Compressibility Inter-particle porosity 0–1.2 0–10 10v/1.2
Carr index 0–50 (%) 0–10 v/5
Cohesion index 0–200 (N) 0–10 v/20
Flowability/powder flow Hausner ratio 1–3 10–0 5(3-v)a
Angle of repose 50–0 (˚) 0–10 10-(v/5)
Powder flow 20–0 (s) 0–10 10-(v/2)
Lubricity/stability Loss on drying 0–10 (%) 10–0 10-v
Hygroscopicity 20–0 (%) 0–10 10-(v/2)
Lubricity/dosage Particles< 50 μm 50–0 (%) 0–10 10-(v/5)
Homogeneity index 0–2 x 10−2 0–10 500v
a Same equation than (30-10v)/2,but simplified.
https://doi.org/10.1371/journal.pone.0196049.t002
Table 1. Parameters and equations used in SeDeMmethodology.
Incidence Parameter Symbol Unit Equation
Dimension Bulk density Da g/ml Da = P/Va
Tapped density Dc g/ml Dc = P/Vc
Compressibility Inter-particle porosity Ie - Ie = Dc-Da/Dc x Da
Carr index IC % IC = (Dc–Da/Dc) 100
Flowability/powder flow Cohesion index IcD N Experimental
Hausner ratio IH - IH = Dc/Da
Angle of repose (α) ˚ Tgα = h/r
Powder flow t ‘‘ s Experimental
Lubricity/stability Loss on drying %HR % Experimental
Hygroscopicity %H % Experimental
Lubricity/dosage Particles< 50 μm %Pf % Experimental
Homogeneity index b (Iϴ) - Eq (1)
a Hardness (N) of the tablets obtained with the product in question, alone or blended with lubricants if highly abrasive.
b Determines particle size. In accordance with the percentages of the different particle-size fractions by applying Eq (1).
c Eq (1) = Iϴ
IƟ ¼ Fm ½100þ ðdm  dm  1ÞFm  1þ ðdmþ 1:dmÞFmþ 1þ ðdm  dm  2ÞFm  2þ    þ ðdm  dm  nÞFm  nþ ðdmþ n  dmÞFmþ n
Fm: percentage of particles in the majority range.
Fm-1: Percentage of particles in the range immediately below the majority range
Fm+1: Percentage of particles in the range immediately above the majority range
n: Order number of the fraction under study, within a series, with respect to the majority fraction
dm: Mean diameter of the particles in the majority fraction
dm-1: Mean diameter of the particles in the fraction of the range immediately below the majority range
dm+1: Mean diameter of the particles in the fraction of the range immediately above the majority range
https://doi.org/10.1371/journal.pone.0196049.t001
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Solubility study of CTZ at phosphate buffer solutions at pH 1.2, 4.5, 6.8, 7.0
Procedure: 100 mg of the active ingredient is weighed in a stoppered test tube of 16 mm diam-
eter and 160 mm high. 0.1 ml of the buffer solution is added. The mixture is stirred vigorously
for 1 minute and introduced into a constant temperature system at 25 ± 0.5˚C for 15 minutes.
If the substance does not dissolve completely, the stirring step is repeated for another minute
and the test tube placed back into the system. If the substance is completely dissolved, CTZ is
defined as "very soluble" in the buffer medium. If CTZ is not dissolved, 0.9 ml of buffer is
added at the same test tube, and the stirring procedure repeated. If the substance is dissolved,
is described as "easily soluble". If not, 2 ml of buffer is added at the same test tube and operate
again according to stirring procedure. If the substance is dissolved, it is described as "soluble".
If the substance does not dissolve completely, add 7 ml at the same test tube of the dissolution
media and repeat the stirring procedure. If the substance does not dissolve, it is described as
“slightly soluble”.
If the substance does not dissolve completely, weigh 10 mg of the active ingredient finely
pulverized into another stoppered test tube, add 10 ml of buffer solution, and operate accord-
ing to stirring procedure. If the substance is dissolved, it is defined as poorly soluble.
If the substance does not dissolve completely, weigh 1 mg of finely powdered active ingredi-
ent into another test tube, adding 10 ml of buffer solution and operate according to stirring
procedure. If the substance is dissolved, it is described as insoluble. The preparation of buffer
phosphate solutions (pH 1.2; 4.5; 6.8 and 7.0), followed Ph Eur 8.7; [39].
Nuclear Magnetic Resonance (NMR)
Varian Gemini-400 (100 MHz) to obtain 1 H and 13 C. The chemical shifts are expressed in
parts per million (ppm) with respect to the central peak of the solvent: CDCI3 d, 7.26 (H) or
DMSO-d6 d, 2.49 (H) as internal patterns.
Infrared Spectroscopy (IR)
FTIR Perkin Elmer model 1600 equipment with according to Ph. Eur 2.2.24 general method
for the determination of IR spectrum.
Powder method of X-ray diffraction (PXRD)
Diffractometer PANalytical X’Pert PROMPD with goniometer θ/θ of 240mm radius, configu-
ration of convergent beam with elliptic mirror and geometry of transmission with sample
holder for capillary with spinner. With Radiation Cu Kα1 (λ = 1.5418 Å´ ) with Lindemann 0.7
mm diameter glass capillary; 45 kV and—40 mA of working power; Windows in the incident
axis that determine the height of the beam to 0.4 mm; Windows 0.02 Soller in the incident
beam and the refracted beam in radians; detector PIXcel with active length of 3,347; Θ/2θ
scanning of 2 to 60˚ 2θcon measurement of step of 0.026 degrees and time of measurement for
200 seconds per step.
UV-Vis Spectrophotometry (UV-Vis)
UV-Vis spectrophotometer SPECORD 205 was used for the UV-Vis wavelength scanning of
the active principle, following Ph. Eur. 8.0 method of identification A of cetirizine dihy-
drochloride: Dissolve 20.0 mg of CTZ in 50 mL of a 10.3 g/L solution of hydrochloric acid R
and dilute to 100.0 mL with the same acid. Dilute 10.0 mL of this solution to 100.0 mL with a
10.3 g/L solution of hydrochloric acid R. Spectral range of 210–350 nm. Absorption maximum
at 231 nm. Specific absorbance at the absorption maximum from 359 to 381.
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Preparation of the DoE and factorial design solutions
All components were weighed, and the solutions tested were manufactured in crystal beakers
by simple mixture of components, with a magnetic stirrer (see Table 3).
Established freeze-drying cycle
Freeze dryer Telstar1 L-3 (Telstar, Terrassa, Spain). Stainless steel tray as support base. A 24–
28 hour freeze-drying cycle, which initiates with a freezing step of -40˚C of 2 hours. Primary
drying step with 95–125 μBar and a secondary drying step at 40˚C. A complete cycle lasts 24–
28 hours. The solutions studied are poured into crystal vials and also into polyvinylchloride
(PVC) molds, using automatic pipette Multipette Plus Eppendorf (Hamburg, Germany). A
vacuum packaging machine Food Saver1 is used to seal the OL, followed by storage in silica
gel desiccant chambers. This cycle was applied in all FDVT.
Differential Scanning Calorimetry (DSC)
DSC 821e Mettler Toledo (Toledo, USA) equipment, using STARe SW 9.30 DSC software,
with the following cycle (CSIC):
25
C to  80 C ð  10C=minÞ
 80 C 1:0 min
 80 C a 25 C ð10 C=minÞ
DSC determined the glass transition temperature (Tg’) of the active principle, excipients
mannitol and PVP K30 and the solutions obtained among them. Samples of 2% CTZ (w/v),
mannitol and PVP K30, and mixtures among them were prepared and filled in a sealed recipi-
ent without applying vacuum. All samples were frozen and then progressively heated.
Freeze-drying microscopy (FDM)
The technique was performed at the center of excellence in freeze-drying (Sant Joan Despı́,
Reig Jofré Group). Olympus objective, model BX51, 10 x. Liquid Nitrogen bomb LNP94-2
(Linkam Scientific Instruments Ltd) to freeze all samples studied. A small drop of sample is
put on a crystal slide, while another crystal slide is put on top of the sample. The chamber is
then sealed, and the sample is frozen by liquid nitrogen. Vacuum is applied and heat to subli-
mate the simple, using a microscope to visualize. Dried substances present a dark aspect.
Table 3. Factorial design 32.
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Using a digital camera, it captures images every two seconds. Once TCO is reached, the dryer
layer is closer to the sublimation interphase generating sparkling dots indicating the loss of
structure (collapse). Further elevation of the temperature results in a severe, more global loss
of structure. Each sample was analyzed twice (see Table 4).
Results
SeDeM diagram
CTZ presented deficient rheological parameters. The Carr index value obtained was sufficient
(r = 5.00). However, the cohesion index (IcD) was null (r = 0); also, its flow parameters were
also null (r = 0), such as the angle of repose and powder flow. CTZ presented particle size infe-
rior of 0.50 μm, which is adequate for its use in a solid state (although the geometrical distribu-
tion was too broad). The parametric indexes of IP (0.42), IPP (5.03) and IGC (4.79) are
insufficient for direct compression, therefore being necessary to consider the preparation of an
oral lyophilisate with this active ingredient as an alternative pharmaceutical technology. The
values of tapped density and bulk density (Dc = 0.276 g/ml and Da = 0.201 g/ml, respectively)
indicated that CTZ presented low density and, as those values were similar, CTZ presented a
good Ie (r = 0). None of the characteristics previously described has no influence in the OL
manufacturing process, not interfering in the correct dispersion of CTZ (a soluble salt) in
aqueous media (previous step to the freeze-drying cycle). Interestingly, from the SeDeM dia-
gram performed, CTZ presents a humidity content of 0.150% and a spontaneous hygroscopic-
ity of 0.200%, showing that CTZ demonstrate an adequate stability behavior in solid form
hence positive for the final stability of an OL (Fig 1 and Table 5).
Solubility studies for pH 1.2, 4.5, 6.8 and 7.0
CTZ is very slightly soluble at pH 1.2 and 4.5 (acid medium) and very soluble at pH 6.8 and 7.0
(neutral medium).
NMR, IR, PXRD and UV-Vis: Identification and characterization CTZ
features
NMR correctly identified the presence of CH2-N from the piperazine ring), the functional
group Ar (aryl), the carboxyl group–COOH, and other groups (CH2-O) as components of the
CTZ (see Fig 2).
The IR spectrum showed an absorption peak at 3500 cm-1 identifying the hydroxyl group
(-OH), which is part of the carboxylic group–COOH. An absorption peak was also determined
at 2627 cm-1 identifying the presence of–COO-. Another absorption peak at 1740 cm-1 was
determined, characteristic of the carboxyl functional group -C = O. Different absorption peaks
were determined about 1500 cm-1, indicating–CH groups, which are present at the aliphatic
chain of the molecule. An absorption peak at 1315 cm-1 was found, corresponding to a -C-N
(indicating the presence of a piperazine ring), and about a 1000 cm-1 an identification peak of
-C-O and at 612 cm-1 there is an absorption peak corresponding to a -C-Cl link (see Fig 3).
Table 4. FDM cycle.
Rate temperature holding time
10˚ C/min TA a -60˚C 3 min (vacuum beginning)
10˚ C/min -60˚C a– 40˚ C 0 min
5˚ C/min -40˚C a 20˚C 0 min
https://doi.org/10.1371/journal.pone.0196049.t004
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As for the PRDX results, the diffractogram of CTZ showed several lines of intensity, indicat-
ing that CTZ is at a crystalline state. Fig 3 shows the diffraction diagram of CTZ obtained in
the main angular range of 2 to 60˚2θ.
The UV-Vis spectrophotometry technique confirms the maximum absorption wavelength
(λ) at 231 nm, complying with the specification of Ph. Eur. for CTZ (see Fig 3).
Fig 1. SeDeM diagram of CTZ.
https://doi.org/10.1371/journal.pone.0196049.g001
Table 5. SeDeM results of CTZ.
Incidence Parameter Signs Unity Experimental values (v) (r) Average incidence
Dimension Bulk density Da g/ml 0.207 2.07 2.42
Tapped density Dc g/ml 0.276 2.76
Compressibility Inter-particle porosity Ie - 1.208 10.00 5.00
Carr index IC % 25.000 5.00
Cohesion Index Icd N 0.000 0.00
Flowability/powder flow Hausner ratio IH - 1.333 8.34 2.78
Angle of repose (α) ˚ 82.804 0.00
Powder flow t sec Not apply 0.00
Lubricity/stability Loss on drying %HR % 0.150 9.85 9.88
Hygroscopicity %H % 0.200 9.90
Lubricity/dosage Particles< 50 μm %Pf μ 0.501 9.90 6.22
Homogeneity index (Iθ) 0.0051 2.55
Parameter index (IP) 0.42
Parameter profile index (IPP) 5.03
Good compression index (IGC) 4.79
https://doi.org/10.1371/journal.pone.0196049.t005
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Design of experiments (DoE)
Freeze-drying viability tests (FDVT)
FDVT were performed to determine the concentration of bulking agents (mannitol and PVP
K30) and the matrix consistency obtained with CTZ, as the final filling dose equivalent of 10
mg of active substance.
In crystal vial
Freeze drying of 1 ml solution of 1% CTZ (W/v) and 0.25, 0.5, 1.0 and 2.0% mannitol (W/v)
tested presented cracked plugs, although due to the higher concentration of mannitol, the con-
centration of 2.0% (W/v) was considered acceptable for further test with PVP K30.
A second batch of 1 ml solution of 1.0% CTZ (W/v) and PVP K 30 at 1.0, 3.0 and 5.0% (W/
v), presented all acceptable plugs, with the 5.0% (W/v) concentration plug with a more com-
pact aspect. A third batch was then performed with 1ml of 1.0% CTZ (W/v), 2.0% (W/v) man-
nitol and 5.0% PVP K30 (W/v). The combination of CTZ, mannitol and PVP K30 presented a
final acceptable result, with no apparent cracking, named X1.
In PVCmold
A fourth batch was performed with X1 and two different PVCmolds, maintaining the 1 ml fill-
ing dose. The first mold had round alveolus of 5 mm high x 15 mm diameter and the second
mold had oval alveolus of 10 mm high x 15 mm long. X1 presented a cracked aspect with the
round alveolus, and a better aspect with the oval alveolus. With the aim of reducing the size of
the OL, a fifth batch was carried out, maintaining the same concentration of bulking agents
and increasing the concentration of CTZ to a 5.0% (W/v) to fill with 0.2 ml of solution (X2)
into smaller round alveolus of 4 mm high x 10 mm diameter. X2 presented again a cracked
aspect.
A sixth batch was tested, maintaining the same concentration of bulking agents and reduc-
ing the concentration of CTZ to a 2.0% (W/v)—solution X3 –with a round alveolus mold, with
Fig 2. Nuclear magnetic resonance of CTZ.
https://doi.org/10.1371/journal.pone.0196049.g002
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0.5 ml volume (with 5 mm high x 12 mm diameter). X3 obtained had no cracked aspect,
although presenting a fragile consistency when extracted from the PVC mold (Table 6).
Therefore, it was determined the concentration of CTZ for the freeze-dried solution X3: 2%
CTZ (W/v), the alveolus for the PVC molds (round alveolus with 5 mm high x 12 mm de
diameter) and the filling dose (0.5 ml = 10 mg). Also, a starting combination of bulking agents
was established of 2.0% (W/v) mannitol and 5.0% (W/v) PVP K30.
Fig 3. PRDX, UV-Vis and IR of CTZ. Fig 3a PRDX, 3b UV-Vis and 3c IR, respectively.
https://doi.org/10.1371/journal.pone.0196049.g003
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To acknowledge whether this proportion between mannitol, PVP K30 and CTZ could pres-
ent metastable forms, a factorial design was carried out with different proportions of the bulk-
ing agents and CTZ.
Determination of Tg’ and detection of metastable forms
A solution of 2% (W/v) CTZ, 2.0, 4.5 and 7.0% (W/v) mannitol and 1.0, 3.0 and 5.0% (W/v)
PVP K30 solutions were analyzed separately (Fig 4). The results showed that CTZ and PVP
K30 did not presented metastable forms. On the other hand, all concentrations studied of
mannitol presented metastable forms (see Table 7).
32 Factorial design (effect of mannitol and PVP K30)
A simple factorial design was carried out with two previous conditions considered for deter-
mining the best combination of excipients: to choose a solution without metastable forms (in
order to ensure drug stability) and with a Tg’ superior to -40˚C (which was the maximum
freezing temperature applied by the freeze-drying equipment). Once determined the calori-
metric feature of each component, the factorial design 32 (see Table 8) was performed, main-
taining the concentration of 2.0% CTZ (W/v). Hence, nine solutions named A, B, C, D, E, F,
G, H and I were studied (see Table 8).
All solutions presented Tg’ superior to– 40˚C. Solutions A (2.0% mannitol and 3.0% PVP
K30), D (2.0% mannitol and 5.0% PVP K30) and E (4.5% mannitol and 5.0% PVP K30) did
not present metastable forms, and all three presented a higher proportion of PVP K30 than
mannitol. On the contrary, solutions B, C, F, G, H and I (Fig 5) presented higher proportions
of mannitol that PVP K30 and metastable forms (Flórez Borges et al., 2015).
Freeze-drying microscopy (FDM) of 32 factorial design
The results obtained from the FDM technique were considered as a tool for obtaining the col-
lapse temperature (TCO) of each solution of the factorial design. TCO is the temperature where
the product loses its structural rigidity and collapses [7]. As for the process of freeze drying,
the product must cool for complete solidification below Tg’ and TCO, and the FDM technique
can be used to identify visibly TCO, providing complementary information to ensure that the
cycle applied (- 40˚C– 40˚C) was suitable for the formulation. Observing the results obtained
(see Table 8) it was observed that solutions A, D and E (without metastable forms) presented
similar TCO (approximately -29.0, -31.0 and -31.0˚C, respectively), whereas solutions B, C, F,
G, H and I (which presented metastable forms) presented TCO ranging from -25.0˚C to -39˚C
(Fig 6). The freeze-drying cycle applied was considered suitable for formulations A, D and E as
it reached -40˚C, which guarantees that each formulation is frozen below its critical tempera-
tures, Tg’ and TCO.
Table 6. First FDVT in PVCmolds.










alveolus dimensions mold Final aspect (cracked/not
cracked)
X1 1 1.0 2.0 5.0 Round 5 mm high x 15 mm
diameter
Cracked
Oval 10 mm high x 15 mm long Not cracked
X2 0.2 5.0 2.0 5.0 Round 4 mm high x 10 mm
diameter
Cracked
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Fig 4. DSC of CTZ, mannitol and PVPK30. Fig 4A and Fig 4C without metastable forms, Fig 4B with metastable
forms.
https://doi.org/10.1371/journal.pone.0196049.g004
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Second FDVT
Solutions A (2.0% mannitol and 3.0% PVP K30), D (2.0% mannitol and 5.0% PVP K30) and E
(4.5% mannitol and 5.0% PVP K30), with similar results of Tg’ and TCO (approx. = -30.0˚C,
respectively), and no metastable forms, were tested with the same freeze-drying cycle (-40˚C to
40˚C) and PVC mold previously established (Table 6, example X3). Solution A matrix pre-
sented a white translucent color with a cracked aspect inside the plug and broke easily when
extracted from the PVC mold; the same occurred with solution D plug. Both matrix A and D
presented the same proportion of mannitol (2.0%) and different proportions of PVP K30
(3.0% and 5.0%, respectively). Solution E plug presented a more compact aspect (white color
with no translucency) and less fragility when extracted from the PVC mold due to an increase
of solid content with 4.5% mannitol in comparison with solutions A and D.
Discussion
The aim of this preformulation study was to develop an oral lyophilizate using CTZ as active
ingredient model. An important aspect of this study is the predetermined and broad (-40 to
40˚c) freeze-drying cycle used, with no possibility of applying any changes, such as annealing,
for instance. Therefore, this boundary had set three main objectives: achieving a formula with
good consistency, absence of metastable forms and Tg’ and TCO that could fit into the cycle,
and not otherwise.
For stability purposes, the use of SeDeM diagram provided valuable data regarding the sta-
bility behavior of CTZ in its solid form. For instance, CTZ presented a humidity content of
0.150% and a spontaneous hygroscopicity of 0.200%, a positive trait for the final stability of an
OL. Also, by DSC, CTZ presented a good calorimetric profile, with no metastability detected.
Table 7. Determination of Tg’ and metastable forms of CTZ and excipients by DSC.
Sample Metastable forms (presence/absence) Tg’ (˚C)
CTZ 2.0% Absence -22.75
MNT 2.0% Presence -27.46
MNT 4.5% Presence -25.31
MNT 7.0% Presence -25.28
PVP K30 1.0% Absence -22.30
PVP K30 3.0% Absence -25.41
PVP K30 5.0% Absence -33.72
https://doi.org/10.1371/journal.pone.0196049.t007
Table 8. 32 Factorial design results of DSC and FDM.
Solution % Mannitol % PVP K30 Metastable form (Absence/Presence) Tg’˚C (DSC) TCO˚C (FDM) Second lyophilisation viability test (Yes/No)
A 2.0 3.0 Absence -29.1 -29.0 Yes
B 4.5 3.0 Presence -36.0 -34.0 No
C 7.0 3.0 Presence -30.4 -29.0 No
D 2.0 5.0 Absence -27.3 -31.0 Yes
E 4.5 5.0 Absence -32.2 -31.0 Yes
F 7.0 5.0 Presence -33.2 -39.0 No
G 2.0 1.0 Presence -34.0 -36.0 No
H 4.5 1.0 Presence - 29.9 -25.0 No
I 7.0 1.0 Presence -29.5 -35.0 No
(W/v).
https://doi.org/10.1371/journal.pone.0196049.t008
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In terms of matrix consistency, FDVT were performed observing aspects such as concentra-
tion of bulking agents, active ingredient and PVC molds; mannitol and PVPK30, were both
initially studied as main bulking agent separately. If only considering the matrix consistency,
mannitol would be the only bulking agent chosen due to the fact that in the first FDVT it pre-
sented a good plug consistency in vial with 2%. However, according to DSC determination of
the different concentrations of mannitol studied (2, 4.5 and 7.0%), it is not recommended to
Fig 5. DSC of solutions F and E. Fig 5A shows a DSC of Solution F with metastable forms, and Fig 5B shows a DSC of
Solution E, without metastable forms.
https://doi.org/10.1371/journal.pone.0196049.g005
Fig 6. FDM of solutions E and F (a and b, respectively).
https://doi.org/10.1371/journal.pone.0196049.g006
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be used as sole excipient, as it presented metastable forms. Therefore, the addition of PVP K30,
which from the start presented a good calorimetric profile with absence of metastable forms
(Fig 4C and Fig 5B), indicates its value as bulking agent with mannitol, conferring the aimed
calorimetric stability needed and adding its valuable characteristics as bulking agent for freeze
dried formulas as well. From the simple 32 factorial design, it was observed that, with the cres-
cent addition of PVP K30, the metastable forms disappeared (Table 8). Nevertheless, Tg’
started to increase, which also is an important aspect to be considered while working within a
predetermined cycle. To sum up, the SeDeMmethod was useful in characterizing CTZ and
giving information regarding its humidity content and hygroscopicity, as PVP K30 was key to
eliminate the metastable forms generated by mannitol. Finally, solution E (4.5% mannitol and
5% PVPK30) was considered the best combination in order to obtain the final OL matrix for
CTZ, by presenting a Tg’ of 32.2˚C, TCO of 31˚C, absence of metastable forms, a less brittle
and more compact aspect when extracted from the round PVC mold of 5 mm high x 12 mm
diameter.
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